Lixia Xu

4.4k total citations · 1 hit paper
106 papers, 2.8k citations indexed

About

Lixia Xu is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Lixia Xu has authored 106 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Molecular Biology, 34 papers in Cancer Research and 24 papers in Oncology. Recurrent topics in Lixia Xu's work include RNA modifications and cancer (23 papers), Cancer-related molecular mechanisms research (18 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (15 papers). Lixia Xu is often cited by papers focused on RNA modifications and cancer (23 papers), Cancer-related molecular mechanisms research (18 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (15 papers). Lixia Xu collaborates with scholars based in China, Hong Kong and United States. Lixia Xu's co-authors include Sui Peng, Xiaoxing Li, Jun Yu, Ming Kuang, Joseph J.�Y. Sung, Junbin Liao, Shuibin Lin, Zihao Dai, Zhenwei Peng and Manling Huang and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Lixia Xu

97 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

N7-Methylguanosine tRNA modification enhances oncogenic mRNA translation and promotes intrahepatic cholangiocarcinoma progression

2021 201 citations Zihao Dai, Hai‐Ning Liu et al. profile →

Peers

Countries citing papers authored by Lixia Xu

Since Specialization

Citations

This map shows the geographic impact of Lixia Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lixia Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lixia Xu more than expected).

Fields of papers citing papers by Lixia Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lixia Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lixia Xu. The network helps show where Lixia Xu may publish in the future.

Co-authorship network of co-authors of Lixia Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Lixia Xu. A scholar is included among the top collaborators of Lixia Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lixia Xu. Lixia Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Intrahepatic Microbial Heterogeneity in Multifocal Hepatocellular Carcinoma and Its Association with Host Genomic and Transcriptomic Alterations 2025 ·Cancer Discovery ·Yinghong Lu, Lixia Xu, (unknown), Weixin Liu, (unknown), (unknown), Na Wang, (unknown), (unknown), (unknown), (unknown), Kaili Fu, (unknown), Xin Liu, (unknown), Chi Chun Wong, Ming Kuang, Jun Yu	2
2	Fe-Doped Carbon Dots-Incorporated In Situ Hydrogel for Near Infrared-Triggered Cascading Photothermal/Thermodynamic Therapy to Boost Cancer Immunity Cycle 2025 ·Biomacromolecules ·F. Du, Lixia Xu, Yu Wang, (unknown), Qinxin Wang, Xiaonan Qiu, Baoding Chen, (unknown)	1
3	Unveiling the functional roles of patient‐derived tumour organoids in assessing the tumour microenvironment and immunotherapy 2024 ·Clinical and Translational Medicine ·Di Chen, Lixia Xu, (unknown), (unknown), Chen Xue	7
4	Molecular mechanisms and therapeutic significance of Tryptophan Metabolism and signaling in cancer 2024 ·Molecular Cancer ·Jing Yan, Di Chen, Zi Ye, Xuqiang Zhu, Xueyuan Li, (unknown), (unknown), Chaoli Zhang, Jingliang Cheng, Lixia Xu, Hongjiang Li, Dongming Yan	47
5	A phase Ia/b trial of ARX788 combined with toripalimab for HER2-low advanced breast cancer (ABC) and other HER2-expressing solid tumors. 2024 ·Journal of Clinical Oncology ·Xiying Shao, Ming Kuang, Zhanhong Chen, Yabing Zheng, Guangliang Li, (unknown), Ping Huang, Wen‐Ming Cao, Lixia Xu, Xiaojia Wang	1
6	Neoadjuvant immune-checkpoint blockade therapy combined with TACE for resectable hepatocellular carcinoma with high recurrence risk: A phase II, single-arm clinical trial (MORNING). 2024 ·Journal of Clinical Oncology ·Li Tan, Lixia Xu, Shunli Shen, (unknown), Yunpeng Hua, (unknown), Li‐Jian Liang, Qiang He, (unknown), Wenxuan Xie, (unknown), Jian Wu, Jiaping Li, Wenzhe Fan, Wenquan Zhuang, Lili Chen, Shi‐Ting Feng, Sui Peng, Jiping Wang, Ming Kuang	1
7	N6 -Methyladenosine Reader YTHDF1 Promotes Stemness and Therapeutic Resistance in Hepatocellular Carcinoma by Enhancing NOTCH1 Expression 2024 ·Cancer Research ·(unknown), Tianhong Su, (unknown), (unknown), (unknown), (unknown), (unknown), Shiyan Wang, Xiaoxing Li, Sui Peng, Ming Kuang, Jun Yu, Lixia Xu	50
8	Personalized drug screening in patient-derived organoids of biliary tract cancer and its clinical application 2023 ·Cell Reports Medicine ·Xiaoxue Ren, (unknown), (unknown), Yubin Xie, Yifan Wu, Shenghua Zhu, (unknown), Dongming Li, Jiaming Lai, Shunli Shen, Jie Lin, Ming Kuang, Xiaoxing Li, Jun Yu, Lixia Xu	29
9	METTL3-m6A-EGFR-axis drives lenvatinib resistance in hepatocellular carcinoma 2023 ·Cancer Letters ·Lina Wang, Qingxia Yang, (unknown), Fei Fang, Kai Lei, Ziqin Liu, (unknown), (unknown), (unknown), Xiaoxing Li, Sui Peng, Ming Kuang, Shuibin Lin, Manling Huang, Lixia Xu	84
10	Cross-talk between Myeloid and B Cells Shapes the Distinct Microenvironments of Primary and Secondary Liver Cancer 2023 ·Cancer Research ·Zhihang Chen, (unknown), Xiaoxue Ren, (unknown), Qian Zhou, Xuxin Ren, Shuling Chen, Lixia Xu, (unknown), Qianwen Zeng, Ming Kuang, Dong‐Ming Kuang, Sui Peng	33
11	Distinct molecular subtypes of papillary thyroid carcinoma and gene signature with diagnostic capability 2022 ·Oncogene ·Shubin Hong, Yubin Xie, Zhen Cheng, Jie Li, Weiman He, Zhuming Guo, Quan Zhang, Sui Peng, Minghui He, Shuang Yu, Lixia Xu, Rengyun Liu, Tianyi Xu, Yunjian Zhang, Yanbing Li, Jiguang Wang, Weiming Lv, Jun Yu, Haipeng Xiao	24
12	Integrative metabolomic characterization identifies plasma metabolomic signature in the diagnosis of papillary thyroid cancer 2022 ·Oncogene ·Shuang Yu, Changan Liu, (unknown), Jie Li, Zhuming Guo, Xinwen Chen, Luyao Zhang, Sui Peng, Shubin Hong, Lixia Xu, Xiaoxing Li, Rengyun Liu, Shuwei Chen, Бин Ли, (unknown), Yanbing Li, Weiming Lv, Jun Yu, Haipeng Xiao	20
13	Targeting tumour-intrinsic N ⁷ -methylguanosine tRNA modification inhibits MDSC recruitment and improves anti-PD-1 efficacy 2022 ·Gut ·Hai‐Ning Liu, Xuezhen Zeng, Xuxin Ren, Yifan Zhang, Manling Huang, Li Tan, Zihao Dai, Jiaming Lai, Wenxuan Xie, Zebin Chen, Sui Peng, Lixia Xu, Shuling Chen, Shunli Shen, Ming Kuang, Shuibin Lin	53
14	METTL1-Mediated m7G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma 2022 ·Cancer Research ·Manling Huang, Jianting Long, (unknown), Yi Zhao, (unknown), Junbin Liao, Kai Lei, Han Xiao, Zihao Dai, Sui Peng, Shuibin Lin, Lixia Xu, Ming Kuang	138
15	Insufficient Radiofrequency Ablation Promotes Hepatocellular Carcinoma Metastasis Through N6‐Methyladenosine mRNA Methylation‐Dependent Mechanism 2021 ·Hepatology ·Tianhong Su, Manling Huang, Junbin Liao, Shuibin Lin, Peng Yu, Jianhua Yang, Yuhong Cai, Shenghua Zhu, Lixia Xu, Zhenwei Peng, Sui Peng, Shuling Chen, Ming Kuang	98
16	NIR responsive tumor vaccine in situ for photothermal ablation and chemotherapy to trigger robust antitumor immune responses 2021 ·Journal of Nanobiotechnology ·Lirong Zhang, Jingjing Zhang, Lixia Xu, (unknown), Jingjin Liu, (unknown), Yunchao Wu, Aihua Gong, Miaomiao Zhang, F. Du	44
17	The Influence of Immune Heterogeneity on the Effectiveness of Immune Checkpoint Inhibitors in Multifocal Hepatocellular Carcinomas 2020 ·Clinical Cancer Research ·Manling Huang, Minghui He, Yu Guo, Heping Li, Shunli Shen, Yubin Xie, Xiaoxing Li, Han Xiao, (unknown), Dongming Li, Baogang Peng, Lijian Liang, Jun Yu, Ming Kuang, Lixia Xu, Sui Peng	29
18	A novel cholchicine/gadolinium-loading tubulin self-assembly nanocarrier for MR imaging and chemotherapy of glioma 2020 ·Nanotechnology ·Lirong Zhang, Dongyan Chen, Jingjing Zhang, Rong Cai, Lixia Xu, (unknown), Shuyu Zhang, Hao Yan, Jingzhou Jiang, F. Du, Aihua Gong	6
19	One-pot synthesis of cerium and praseodymium co-doped carbon quantum dots as enhanced antioxidant for hydroxyl radical scavenging 2019 ·Nanotechnology ·Shengqiang Zou, (unknown), Lin Wu, Huixiang Ju, Mingzhong Sun, Rong Cai, Lixia Xu, Yuhua Gong, Aihua Gong, Miaomiao Zhang, F. Du	33
20	IDDF2018-ABS-0140 The crosstalk of MTORC1 and DNA methylation in hepatocellular carcinoma 2018 ·Judeng Zeng, Mengke Chen, Ning Zhang, Lixia Xu, Yang Yang, Xiaoyi Xu, Hui‐Yun Wang, (unknown)	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact